Data / Drug companies / TruPharma, LLC
TruPharma, LLC: 85 products in the FDA NDC directory, labeler code 52817
TruPharma, LLC (labeler code 52817) lists 85 products in the FDA National Drug Code Directory, covering 40 finished drugs by generic name. By type: 85 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 16, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 52817
- Products in commercial distribution
- 85
- Packages
- 136
- Finished drugs by generic name
- 40
- Prescription products
- 85
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 7
- Flagged as original packager
- 68 of 68 products that carry the flag
- Started marketing in the last 12 months
- 14
- Products with a marketing end date set
- 3
- Earliest marketing start
- August 1, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 74 | 87.1% |
| Authorized generics (NDA) | 9 | 10.6% |
| Other unapproved drugs | 1 | 1.2% |
| New drug applications (NDA) | 1 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 85 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Metoprolol tartrate | 10 | 46 |
| Clonidine transdermal system | 6 | 2 |
| Baclofen | 5 | 65 |
| Clonidine hydrochloride | 4 | 45 |
| Sildenafil | 4 | 53 |
| Tramadol hydrochloride | 3 | 44 |
| Bisoprolol fumarate | 3 | 25 |
| Oxazepam | 3 | 6 |
| Midodrine hydrochloride | 3 | 34 |
| Cyclobenzaprine hydrochloride | 3 | 61 |
| Carbidopa and levodopa | 3 | 41 |
| Acetazolamide | 2 | 37 |
| Sertraline hydrochloride | 2 | 55 |
| Sapropterin dihydrochloride | 2 | 10 |
| Triamterene capsules | 2 | 2 |
| Naproxen | 2 | 58 |
| Cyproheptadine hydrochloride | 2 | 24 |
| Metformin hydrochloride | 2 | 79 |
| Oxybutynin chloride | 2 | 45 |
| Trazodone hydrochloride | 2 | 39 |
| Glipizide | 1 | 39 |
| Triamcinolone acetonide | 1 | 77 |
| Aminocaproic acid | 1 | 23 |
| Apomorphine hydrochloride | 1 | 2 |
| Hydrocortisone acetate, pramoxine hcl | 1 | 5 |
| Nitroglycerin | 1 | 40 |
| Ramelteon | 1 | 29 |
| Clozapine | 1 | 13 |
| Levocarnitine | 1 | 10 |
| Primidone | 1 | 23 |
| Acetic acid | 1 | 7 |
| Betamethasone dipropionate usp, 0.05% | 1 | 1 |
| Dapsone gel, 5% | 1 | 2 |
| Ethacrynic acid | 1 | 10 |
| Clonazepam | 1 | 36 |
| Clonidine | 1 | 9 |
| Prednisolone oral | 1 | 4 |
| Clotrimazole topical solution usp, 1% | 1 | 5 |
| Dapsone | 1 | 26 |
| Sucralfate oral | 1 | 6 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 29 | 34.1% |
| Tablet, film coated | 20 | 23.5% |
| Solution | 9 | 10.6% |
| Patch | 6 | 7.1% |
| Capsule | 5 | 5.9% |
| Tablet, coated | 2 | 2.4% |
| Cream | 2 | 2.4% |
| Powder, for solution | 2 | 2.4% |
| Tablet, delayed release | 2 | 2.4% |
| Ointment | 2 | 2.4% |
| Suspension | 2 | 2.4% |
| Gel | 2 | 2.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sertraline Hydrochloride | 52817-224 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2026 |
| Sertraline Hydrochloride | 52817-223 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2026 |
| Trazodone Hydrochloride | 52817-396 | Tablet, film coated | Generic drugs (ANDA) | September 3, 2026 |
| Trazodone Hydrochloride | 52817-395 | Tablet, film coated | Generic drugs (ANDA) | September 3, 2026 |
| Clonazepam | 52817-305 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Prednisolone | 52817-860 | Solution | Generic drugs (ANDA) | August 4, 2026 |
| Oxybutynin Chloride | 52817-261 | Tablet | Generic drugs (ANDA) | July 28, 2026 |
| Cyproheptadine Hydrochloride | 52817-415 | Tablet | Generic drugs (ANDA) | June 1, 2026 |
| Clonidine hydrochloride | 52817-183 | Tablet | Generic drugs (ANDA) | April 13, 2026 |
| Clonidine Transdermal System USP, 0.3 mg/day | 52817-507 | Patch | Authorized generics (NDA) | March 30, 2026 |
| Clonidine Transdermal System USP, 0.2 mg/day | 52817-506 | Patch | Authorized generics (NDA) | March 30, 2026 |
| Clonidine Transdermal System USP, 0.1 mg/day | 52817-505 | Patch | Authorized generics (NDA) | March 30, 2026 |
| Sapropterin Dihydrochloride | 52817-851 | Powder, for solution | Generic drugs (ANDA) | January 30, 2026 |
| Sapropterin Dihydrochloride | 52817-850 | Powder, for solution | Generic drugs (ANDA) | January 30, 2026 |
| Bisoprolol Fumarate | 52817-268 | Tablet, film coated | Generic drugs (ANDA) | March 7, 2025 |
| Nitroglycerin | 52817-835 | Ointment | Generic drugs (ANDA) | December 2, 2024 |
| Dapsone | 52817-832 | Gel | Generic drugs (ANDA) | November 20, 2024 |
| Sucralfate | 52817-840 | Suspension | Generic drugs (ANDA) | April 1, 2024 |
| Dapsone | 52817-831 | Gel | Generic drugs (ANDA) | March 1, 2024 |
| Baclofen | 52817-318 | Tablet | Generic drugs (ANDA) | February 5, 2024 |
| Metoprolol tartrate | 52817-254 | Tablet | Generic drugs (ANDA) | January 17, 2024 |
| Metoprolol tartrate | 52817-253 | Tablet | Generic drugs (ANDA) | January 17, 2024 |
| Metoprolol tartrate | 52817-252 | Tablet | Generic drugs (ANDA) | January 17, 2024 |
| Metoprolol tartrate | 52817-251 | Tablet | Generic drugs (ANDA) | January 17, 2024 |
| Metoprolol tartrate | 52817-250 | Tablet | Generic drugs (ANDA) | January 17, 2024 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.